|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
The positive association between MetS and GEP-NET characteristics further highlights the potential link between the two conditions.
|
31533348 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
However, there is no information about a possible role of NLR, PLR and PWR as predictor of presence of metastasis or multifocal disease in patients undergoing surgery with curative intent for midgut NET.
|
31520198 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although there is no category corresponding to NET G3 in the current classification of lung tumors, we consider that our tumors may correspond to NET G3 and identification of this subset is relevant for therapeutic management.
|
31511024 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3.
|
31511024 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The category of grade 3 neuroendocrine tumor (NET G3) was newly introduced in the 2017 World Health Organization (WHO 2017) classification of neuroendocrine neoplasms of the pancreas.
|
31511024 |
2019 |
|
Carcinoid Tumor
|
0.050 |
GeneticVariation
|
phenotype |
BEFREE |
Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3.
|
31511024 |
2019 |
|
Carcinoid tumor no ICD-O subtype
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3.
|
31511024 |
2019 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
There is no category corresponding to NET G3 in the current WHO 2015 classification of lung tumors.
|
31511024 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stratified by the tumour grade (WHO 2010 classification), we observed 64.0% of NET G1, 24.7% of NET G2, and 11.3% of NEC.
|
31467527 |
2019 |
|
Mental Depression
|
0.600 |
Biomarker
|
disease |
BEFREE |
The serotonin transporter belongs to the family of sodium-chloride coupled neurotransmitter transporter and is related to depression in humans.
|
31442583 |
2019 |
|
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The serotonin transporter belongs to the family of sodium-chloride coupled neurotransmitter transporter and is related to depression in humans.
|
31442583 |
2019 |
|
Depressed mood
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The serotonin transporter belongs to the family of sodium-chloride coupled neurotransmitter transporter and is related to depression in humans.
|
31442583 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
Biomarker
|
disease |
BEFREE |
NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2.
|
31428952 |
2019 |
|
Diabetic Retinopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Since the NET could provide negative-charged surface for factor XII activation and the activated factor XII (XIIa) can initiate kallikrein-kinin system, this study investigated whether patients with DR show activation of NET, factor XII and kallikrein-kinin system.
|
31426112 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
Biomarker
|
disease |
BEFREE |
No prognostic difference was detected between NET G3 and NEC patients after 5 year DFS.
|
31422400 |
2019 |
|
Neuroendocrine tumor G2 (NET G2)
|
0.090 |
Biomarker
|
disease |
BEFREE |
NET G3 patients had a worse outcome than NET G1 (p<0.01) and NET G2 patients (p=0.02), respectively.
|
31422400 |
2019 |
|
Attention deficit hyperactivity disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subgroup of 18 patients with ADHD and 18 healthy controls underwent positron emission tomography (PET) with the radioligand (S,S)-[<sup>18</sup>F]FMeNER-D<sub>2</sub> to quantify the NET in several brain areas in vivo.
|
31383926 |
2019 |
|
Hyperactive behavior
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET.
|
31383926 |
2019 |
|
Malignant Head and Neck Neoplasm
|
0.030 |
Biomarker
|
disease |
BEFREE |
Advancing interdisciplinary research in head and neck cancer through a multicenter longitudinal prospective cohort study: the NETherlands QUality of life and BIomedical Cohort (NET-QUBIC) data warehouse and biobank.
|
31382921 |
2019 |
|
Head and Neck Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Advancing interdisciplinary research in head and neck cancer through a multicenter longitudinal prospective cohort study: the NETherlands QUality of life and BIomedical Cohort (NET-QUBIC) data warehouse and biobank.
|
31382921 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
NET gene polymorphism might be associated with the risk of T2DM whereas; eNOS gene polymorphism do not confer any risk of T2DM in North Indian Ethnic group.
|
31377977 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Taking full advantage of positron emission tomography (PET) technology, fluorine-18-labelled radiotracers targeting norepinephrine transporter (NET) have potential applications in the diagnosis and assessment of cardiac sympathetic nerve conditions as well as the delineation of neuroendocrine tumours.
|
31332629 |
2019 |
|
Adrenal Gland Pheochromocytoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
High-specific-activity, carrier-free I-131-MIBG has been developed over the past two decades as a novel therapy for patients with metastatic pheochromocytomas and paragangliomas that express the norepinephrine transporter.
|
31330766 |
2019 |
|
Paraganglioma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High-specific-activity, carrier-free I-131-MIBG has been developed over the past two decades as a novel therapy for patients with metastatic pheochromocytomas and paragangliomas that express the norepinephrine transporter.
|
31330766 |
2019 |
|
Pheochromocytoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
High-specific-activity, carrier-free I-131-MIBG has been developed over the past two decades as a novel therapy for patients with metastatic pheochromocytomas and paragangliomas that express the norepinephrine transporter.
|
31330766 |
2019 |